Multicenter retrospective survey of all CD patients treated with infliximab in 8 University hospitals of the Madrid area (Spain) with a minimum follow up of 14wks.
169 patients included (48%males, mean age 39 卤 12 yrs). 64%of them had perianal disease. 82%were under immunosuppressants. 1355 infliximab infusions administered (mean 8, range 1-30). 90%response rate and 48%remission rate were obtained with induction therapy. 73%followed maintenance treatment, and 78%of them maintained or improved the response after a mean follow up of 28 months (range 3.5-86). 24 patients lost response during the follow up, after a mean of 41wks (range 6-248). Only the prescription of maintenance therapy was predictive factor for favourable response (p < 0.01). 17 infusion reactions were reported (10%of the patients, 1.2%of the infusions; only one case was severe) and were the cause of treatment withdrawal in 7 patients. Co-treatment with immunosuppressive drugs and maintenance infliximab therapy were protective factors for infusion reactions (p < 0.05). Other adverse events occurred in 26%of the patients, and were cause of treatment withdrawal in 7 patients.
Infliximab is effective and safe for CD management but concomitant immunosuppressive drugs and maintenance treatment should be prescribed to obtain the best outcome. That confirms in a real life clinical setting the favourable results obtained in randomized clinical trials.